Since mouse microbiome profiles often highly correlate with body weight and fat composition, this study was designed to test whether the cecal microbiomes of DIO mice treated with NNMTi and LD were comparable to the microbiomes of age-matched lean counterparts and distinct from microbiomes of DIO mice maintained on a high-fat Western diet (WD) or subjected to LD switch alone
Side Effects & Safety Mild GI discomfort most common, usually transient in the first week Slight stimulant effect increased energy/alertness, especially early on Headaches occasional, typically mild and dose-related Mild insomnia if taken too late in the day No human clinical safety data all safety information from preclinical studies and community reports No liver toxicity observed in animal studies at therapeutic doses Unknown drug interactions theoretically could interact with NAD+-dependent pathways Core Supplies for This Protocol The essentials for running any reconstituted injectable: cold storage, accurate syringes, alcohol prep pads, and metabolic tracking
Persistent or severe symptoms suggest dose reduction or potential sensitivity
Recovery-Heavy Phases: Combine with BPC-157 for Recovery and TB-500: Peptide Benefits after injury or joint stress
Clinical trial results showed modest and variable weight loss outcomes
When it becomes overactive, it essentially tells your cells to store more fat and burn less energy, while also depleting your valuable NAD+ reserves
